Cargando…
An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats
BACKGROUND: Treatment of diabetes mellitus (DM) in cats typically requires insulin injections q12h‐q24h, posing a major compliance barrier for caregivers. Novel treatments enabling decreased injection frequency while maintaining safety are highly desirable. Insulin fused with feline immunoglobulin f...
Autores principales: | Gilor, Chen, Hulsebosch, Sean E., Pires, Jully, Bannasch, Michael J., Lancaster, Thomas, Delpero, Andrea, Ragupathy, Ramya, Murikipudi, Sylaja, Zion, Todd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478034/ https://www.ncbi.nlm.nih.gov/pubmed/34190365 http://dx.doi.org/10.1111/jvim.16150 |
Ejemplares similares
-
Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs
por: Hulsebosch, Sean E., et al.
Publicado: (2022) -
Accuracy of a flash glucose monitoring system in cats and determination of the time lag between blood glucose and interstitial glucose concentrations
por: Del Baldo, Francesca, et al.
Publicado: (2021) -
Evaluation of a machine learning tool to screen for hypoadrenocorticism in dogs presenting to a teaching hospital
por: Reagan, Krystle L., et al.
Publicado: (2022) -
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021) -
Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs
por: Munro, Matthew J. L., et al.
Publicado: (2021)